Our policy is focused on long-term investing, and Serbia is a good place for that. We made the decision to invest in Serbia two years ago, when the situation in this country was even more uncertain, and we concluded that Serbia was heading in a good direction. We are interested in investing in the fields we are usually engaged in – consumer goods, health care, IT technologies – Robert Manz, CEO of Enterprise Investors and a member of the Managing Board of PharmaSwiss, said to the press in Belgrade on May 28. By the way, Swiss company PharmaSwiss is going to have a new drugs factory built in Zemun, and the value of that greenfield investment is EUR 20m.
As the company’s representatives announced on the occasion of the celebration of the tenth anniversary of operations in the market of Serbia, the works will commence in the last quarter of this year. It is expected that the factory will be put in operation by the end of 2011 and that few hundred workers will get jobs in it. – The share of PharmaSwiss in the market of Serbia is the largest of all shares in the markets that the company operates in, and it is present in 19 countries in Europe and acts as an exclusive agent of innovative and biotechnological pharmaceutical companies and their products.
Regardless of the crisis that is present everywhere, the situation in Serbia is now much better for investments than few years ago – said the company’s Executive Director and founder Petr Nemec.
